Assistant Professor Receives CIHR Grant for Ovarian Cancer Project

Recently, Dr. Michelle Jacobson, Assistant Professor with the Department of Obstetrics and Gynaecology, was awarded a Canadian Institutes of Health Research (CIHR) grant for research on ovarian cancer. Dr. Jacobson is a co-investigator on the project entitled "Reducing ovarian cancer risk by regulating age-associated ovarian fibrosis", and is joined by principal investigator Dr. Barbara Vanderhyden (University of Ottawa), as well as fellow co-investigators Dr. Sarah Strickland (University of Ottawa) and Dr. Dominique Trudel (Université de Montréal). The CIHR will be providing the research team with $680,850 over five years.

"This study is important because ovarian cancer is a disease that has no modality for screening and presents with a low survival in later stages," said Dr. Jacobson. "This study will potentially repurpose a commonly used and well tolerated medication for ovarian cancer chemoprophylaxis in BRCA carriers, who have a 30x population risk of developing ovarian cancer."

The project summary: "For most women, the largest risk factor for ovarian cancer is the monthly ovulation. Oral contraceptives prevent ovulation and can reduce ovarian cancer risk by up to 35%, but how ovulation increases risk is not clear. In trying to find an explanation, our lab has found that ovaries from aged mice and post-menopausal women, which have had many ovulations, harbor a population of cells that are known to suppress the activity of the immune system. These cells were not found in young ovaries. We predict that these cells play a critical role in allowing both primary and metastatic cancers to grow in the ovary. The accumulation of immune suppressing cells in the aging ovary is associated with fibrosis. We have created a mouse model that develops ovarian fibrosis and the question we are asking is: Can this process be blocked or reversed? Metformin, a drug used mostly by diabetes patients, has been shown to reduce fibrosis in other tissues, and diabetic women who take metformin have a dramatic decrease in the incidence of ovarian cancer. We therefore propose to determine the contribution of fibrosis to the recruitment of immunosuppressive cells to the ovary, determine how the development of fibrosis is accelerated in women with BRCA mutations, and explore how metformin can prevent or reverse these changes. Our results would open the door to the possibility that metformin could be used for ovarian cancer prevention in women at high risk."

To learn more about this study, please visit the CIHR website.

Congratulations, Dr. Jacobson!

_____________________________________________________________

Don't want to miss a post? Follow us on social media for more news!

FACEBOOK | INSTAGRAM | TWITTER

If you would like to be a guest blogger, please contact us at obgyn@utoronto.ca.